Navigation Links
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results

First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline

BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced the positive clinical results of its Phase IIa Alkaline Phosphatase (AP) trial for patients with ulcerative colitis, a chronic and relapsing inflammatory bowel disease affecting the colon.

In this recent trial, AP was used in the treatment of 21 hospitalised patients suffering from moderate to severe ulcerative colitis, who had failed to show improvement using existing treatments of steroids and immunosuppressants. The AP therapy was administered through a duodenal drip at a dose of 10mg AP per day.

In the trial, patients showed clinically relevant improvement after the seven day treatment period, in the two main clinical parameters (Truelove-Witts and Mayo scores) measured three weeks after starting the AP trial.

Patient response rates after three weeks were 63% on the Truelove-Witts score and 47% on the Mayo score. Complete remission after three weeks was reached by 21% of patients on the Truelove-Witts score and by 5% of patients on the Mayo score. After 63 days, 79% of patients showed a response and 26% of patients were in complete remission according to the Truelove-Witts score. No serious adverse effects or treatment-related withdrawals were reported.

AP is a unique therapy for ulcerative colitis based on the dephosphorylation and detoxification of a group of bacterial endotoxins called lipopolysaccharides, which can cause inflammation in the colon. AM-Pharma's patented AP treatment has already shown positive results in trials for treatment of acute renal failure and sepsis.

Bart Wuurman, CEO commented: "It's fantastic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:4/23/2015)... 2015  AbbVie (NYSE: ABBV ) has announced ... accepted its New Drug Application (NDA) and granted priority ... treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). ... chronic genotype 4 (GT4) hepatitis C virus (HCV) infection. ... therapy being evaluated by the FDA for patients in ...
(Date:4/23/2015)... April 23, 2015 /CNW/ - Health Canada is working ... to update the safety information regarding the risk of ... when these products are used at high doses (at ... and duration of use. Ibuprofen is a ... relief, and to reduce inflammation. The majority of ibuprofen ...
(Date:4/23/2015)... Surna, Inc. (OTCQB: SRNA), a technology company ... and systems for controlled environment agriculture ("CEA") with ... host a shareholder conference call to discuss its ... PM Eastern Standard Time/1:15 PM Pacific Standard Time. ... listen-in only, but will include a Q&A session ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
... BEIJING , July 15 /PRNewswire-Asia/ -- Sinovac Biotech ... China , announced today that it,held its 2010 Annual Meeting of ... Beijing Time. The required quorum, a majority of the ... was held,concurrently at No. 39 Shangdi Xi Road, Haidian District, ...
... SUNNYVALE, Calif. , July 15 Premier ... and 67,000-plus other healthcare sites working together to achieve ... provider of FDA-cleared Electronic Brachytherapy Systems, announced the execution ... exclusive three-year contract for brachytherapy systems with Premier Purchasing ...
Cached Medicine Technology:Sinovac Holds 2010 Annual Meeting of Shareholders 2Xoft Announces Exclusive Contract With Premier for Electronic Brachytherapy 2Xoft Announces Exclusive Contract With Premier for Electronic Brachytherapy 3
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair ... following statement following the deadly earthquake in Nepal: , ... in the deaths of more than 1,000 people. ... Nepal, Bangladesh, India and other parts of South Asia. ... the people of Nepal and the families of the ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Carinsurancequotesinfo.com has ... find low cost auto insurance for flatbed ... heavy goods and sometimes other vehicles. They are mainly ... insurance. The newly released blog post explains that by ... for trucks, vans and other commercial vehicles. , It ...
(Date:4/25/2015)... Caicos Islands, BWI (PRWEB) April 25, 2015 ... (PLS) has celebrated three months of successfully welcoming visitors ... January 5, 2015. , As part of a ... of Providenciales airport was completely redesigned to speed up ... up the process of getting out of the airport ...
(Date:4/25/2015)... York (PRWEB) April 25, 2015 The URO ... Jerry Blaivas has been chosen by the New York Academy ... contributions to medicine in the field of Urology. , Dr. ... in his speciality, Genito-Urinary diseases. He was a man ... the field of urology. Not only did he devote ...
(Date:4/25/2015)... Minnesota (PRWEB) April 25, 2015 For thirteen ... the premier income protection education event in the nation! This ... with The Plus Group, US to take DI Day on ... , George G. Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief ... Cities DI Day reflects on the change by stating, "The ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Secura Consultants Takes DI Day On The Road 2
... attention of the entire world appears to be focused on the ... globe. AIDS which has already taken a toll of 25 million ... same level of attention. The AIDS program does not even have ... ,The areas that are worst affected by AIDS are mostly ...
... beneficial effects of physical activities such as running, jogging on ... has now been found by neuroscientists from Germany that running ... boost of memory. // ,The study ... sessions per week followed by which they had to take ...
... Vietnamese patients who were infected with the H5N1 bird flu ... Roche drug, Tamiflu. The virus appears to have developed a ... among medical circles. The virus was seen to mutate in ... 274Y resistant strains were seen in both cases. ...
... study conducted at the University of Texas has revealed ... to develop heart problems compared to their counterparts. // ... be afflicted with the disease worldwide with approximately 10 ... many factors that contribute to this disease including age, ...
... treatment now offers hope for treatment of Ambylopia or lazy eye ... the combined efforts of researchers at the USC and three other ... normal, although there may a compromise in the vision even when ... vision loss. Until now, the condition has been regarded to be ...
... launched by the pharmaceutical company Pfizer in 30 different cities ... to suffer from erectile dysfunction.// The drug company is expected ... the market within the next two years according to K.G. ... Indian wing. ,Several factors regarding the Indian Pharmaceutical ...
Cached Medicine News:Health News:Flu Pandemic Gets More Attention Than AIDS 2Health News:Erectile Dysfunction Drug Viagra Launched In India By Pfizer 2
... System is a single-use, disposable needle loading ... into a Bard BrachyStar needle for interstitial ... radiation safety shield, inner compartment that holds ... fitting that connects the cartridge to the ...
... Holter Monitoring System uses technology developed by ... first true 12-lead digital Holter recorder in ... beat contained in the 24-hour study provides ... work done by the Q-12 digital recorder ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
... any clinical setting, offering an exclusive ... procedure. Customize Delphis™ to your exact ... Pocket PC, a Touchpad PC Tablet ... technology allows you to focus on ...
Medicine Products: